A variety of metabolic regulation methods of adenosine levels have been developed, and several clinical studies have been carried out to evaluate the initial efficacy of new inhibitors of CD39, CD73, or A2aR signaling pathways in cancer therapy. The gene discussed is ENTPD1; the disease is cancer.